FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2085309971> ?p ?o ?g. }

• W2085309971 endingPage "487" @default.
• W2085309971 startingPage "486" @default.
• W2085309971 abstract "The meta-analysis by Sotiriadis et al.1 regarding progestogen safety is a very informative, much appreciated synthesis of trial data. The findings validate similar conclusions for efficacy by Romero et al., with reduction of respiratory distress syndrome (RDS) after exposure to vaginal progesterone for a short cervix and, supporting prior observations2, 3, quantify statistically significant harms related to exposure to synthetic 17-hydroxyprogesterone caproate (17-OHPC) in multiple gestations. The Food and Drug Administration (FDA) in the USA dealt with the safety of different progestogens in pregnancy in 1999 when addressing teratogenicity and opined that it is ‘… inappropriate to consider these drugs a single class…’, thereby suggesting these agents should be interrogated individually for safety assessments4. This approach appears optimal for current safety concerns as differing molecular structures, pharmacokinetics and pharmacodynamics of the progestogens utilized for preterm birth prevention have been demonstrated. There is ample evidence documenting that 17-OHPC is not progesterone or a prodrug of any natural progestogen and that the interaction with progesterone receptors differs between these drugs5, 6. 17-OHPC appears to act as a partial agonist for these receptors not a full agonist for particular responses7. When discussing harm related to any intervention, an essential consideration is biologic plausibility for the mechanism8. Sotiriadis et al.1 opt not to present an assessment for biologic plausibility of harm related to exposure to these agents. Their investigation suggested that this class of drugs was associated with perinatal death, RDS and composite adverse outcome in multiple gestations. However, devising a cogent argument for harm related to supplemental administration of natural progesterone to explain these outcomes is exceedingly difficult. The placental production of progesterone differs markedly during gestation, allowing human pregnancy itself to act as an informative setting for safety/toxicity. For example, if the progesterone bioavailability resulting from placental production at term or near term in a singleton or multiple gestation alone is considered safe and if this bioavailability exceeds combined placental and supplemental progesterone exposure in the midtrimester, how can dosing this natural hormone be considered harmful? Also, the apparent lack of a harmful effect related to greater bioavailability of natural progesterone at any particular gestational age in cases of higher order multiple compared with twin compared with singleton pregnancies raises additional questions regarding biologic plausibility for harm. In their meta-analysis, Sotiriadis et al.1 found that when progestogens were analyzed individually, harm was not identified for each agent and was only found related to the synthetic drug in multiple gestations. In support, to date, no Phase III study in singleton or multiple pregnancies has reported a statistically significant association for harm related to natural progesterone exposure. The authors may wish to propose considerations for biologic plausibility related to their findings of harm in multiple gestations or suggest limitations for this type of analysis. Given observations documenting a possible benefit for natural progesterone therapy from Phase III trials enrolling twins9, 10 (Table 1), safety analyses of these compounds as a class rather than as individual drugs may cast too dark a shadow on this therapeutic strategy, perhaps unnecessarily limiting investigation into populations of multiple pregnancies that could derive some benefit, and may unnecessarily force us to relive history. In summary, progestogen safety should include a consideration of biologic plausibility for mechanism of harm when concerns are identified. The analysis should optimally be based on the individual agent rather than the class of drug. Such a strategy will allow obstetricians to fully explore the capabilities of supplemental progesterone to enhance the function of the cervix, decidua, fetal membranes or myometrium in certain vulnerable populations to improve pregnancy outcomes. (1) J. M. O'Brien was involved in studies of progesterone gel treatment for preterm birth prevention sponsored by a maker of progesterone gel. (2) J. M. O'Brien serves on advisory boards and as a consultant for Watson Pharmaceuticals, a company with a financial interest in marketing vaginal progesterone gel for preterm birth prevention. (3) J. M. O'Brien and others are listed in a patent on the use of progesterone compounds to prevent preterm birth. (US Patent Number 7,884,093: Progesterone for the Treatment and Prevention of Spontaneous Preterm Birth). J. M. O'Brien*, * Division of Maternal Fetal Medicine, University of Kentucky, 800 Rose Street, Lexington, KY, USA" @default.
• W2085309971 created "2016-06-24" @default.
• W2085309971 creator A5026070442 @default.
• W2085309971 date "2012-09-25" @default.
• W2085309971 modified "2023-09-26" @default.
• W2085309971 title "Progestogen safety: implications for meta-analysis" @default.
• W2085309971 cites W1993574752 @default.
• W2085309971 cites W2047753213 @default.
• W2085309971 cites W2048345592 @default.
• W2085309971 cites W2059935337 @default.
• W2085309971 cites W2089017675 @default.
• W2085309971 cites W2127120959 @default.
• W2085309971 cites W2144088431 @default.
• W2085309971 cites W2150079193 @default.
• W2085309971 doi "https://doi.org/10.1002/uog.12284" @default.
• W2085309971 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23008105" @default.
• W2085309971 hasPublicationYear "2012" @default.
• W2085309971 type Work @default.
• W2085309971 sameAs 2085309971 @default.
• W2085309971 citedByCount "1" @default.
• W2085309971 countsByYear W20853099712016 @default.
• W2085309971 crossrefType "journal-article" @default.
• W2085309971 hasAuthorship W2085309971A5026070442 @default.
• W2085309971 hasBestOaLocation W20853099711 @default.
• W2085309971 hasConcept C126322002 @default.
• W2085309971 hasConcept C131872663 @default.
• W2085309971 hasConcept C177713679 @default.
• W2085309971 hasConcept C197934379 @default.
• W2085309971 hasConcept C2779234561 @default.
• W2085309971 hasConcept C2780572241 @default.
• W2085309971 hasConcept C46973012 @default.
• W2085309971 hasConcept C54355233 @default.
• W2085309971 hasConcept C71315377 @default.
• W2085309971 hasConcept C71924100 @default.
• W2085309971 hasConcept C86803240 @default.
• W2085309971 hasConcept C98274493 @default.
• W2085309971 hasConceptScore W2085309971C126322002 @default.
• W2085309971 hasConceptScore W2085309971C131872663 @default.
• W2085309971 hasConceptScore W2085309971C177713679 @default.
• W2085309971 hasConceptScore W2085309971C197934379 @default.
• W2085309971 hasConceptScore W2085309971C2779234561 @default.
• W2085309971 hasConceptScore W2085309971C2780572241 @default.
• W2085309971 hasConceptScore W2085309971C46973012 @default.
• W2085309971 hasConceptScore W2085309971C54355233 @default.
• W2085309971 hasConceptScore W2085309971C71315377 @default.
• W2085309971 hasConceptScore W2085309971C71924100 @default.
• W2085309971 hasConceptScore W2085309971C86803240 @default.
• W2085309971 hasConceptScore W2085309971C98274493 @default.
• W2085309971 hasIssue "4" @default.
• W2085309971 hasLocation W20853099711 @default.
• W2085309971 hasLocation W20853099712 @default.
• W2085309971 hasOpenAccess W2085309971 @default.
• W2085309971 hasPrimaryLocation W20853099711 @default.
• W2085309971 hasRelatedWork W2120298409 @default.
• W2085309971 hasRelatedWork W2186200056 @default.
• W2085309971 hasRelatedWork W2344177211 @default.
• W2085309971 hasRelatedWork W2409168192 @default.
• W2085309971 hasRelatedWork W3048306897 @default.
• W2085309971 hasRelatedWork W3163987424 @default.
• W2085309971 hasRelatedWork W3181785047 @default.
• W2085309971 hasRelatedWork W4200420510 @default.
• W2085309971 hasRelatedWork W4281694272 @default.
• W2085309971 hasRelatedWork W4291111811 @default.
• W2085309971 hasVolume "40" @default.
• W2085309971 isParatext "false" @default.
• W2085309971 isRetracted "false" @default.
• W2085309971 magId "2085309971" @default.
• W2085309971 workType "article" @default.